2 results
Approved WMOCompleted
Part A - CX-2009 Monotherapy: Every 21-Day Dosing RegimenThe primary objective of Part A is to determine the safety profile of CX-2009, the maximum tolerated dose (MTD)/recommended Phase 2 dose (RP2D), and the dose-limiting toxicities(DLTs) of CX-…
Approved WMORecruiting
Primary Objective: Assess the ability of MRCP+ and LMS to detect change in total biliary volume and cT1 value, 8 weeks after endoscopic treatment of dominant strictures, by a clinical decision rule.Secondary Objective(s): Comparison of baseline MRCP…